Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Extended-interval tarlatamab dosing shows consistent activity and safety in previously ...

12 September 2026 · By · Wire by Fusion42

Published

12 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at eurekalert.org →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

Extended-interval dosing regimens of tarlatamab demonstrated consistent efficacy and safety profiles compared to the established every-two-week regimen in previously treated small cell lung cancer patients, offering greater treatment flexibility.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have new options to simplify treatment schedules for small cell lung cancer patients with tarlatamab dosing every three or four weeks. This shift in dosing frequency could improve patient adherence and expand your clinical offering without compromising safety or efficacy.

◆ Coverage

1 source · 12 Sep 2026

◆ Related on Wire

◆ Topics

Biotechtarlatamabsmall-cell-lung-cancerdosing-regimenclinical-trialoncology